Everolimus

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and proliferation.
• Deregulation of the mTOR pathway is common in various cancers.
• Everolimus is an oral mTOR inhibitor targeting this pathway.

Purpose of the Study:

• To summarize the approved indications and ongoing research for everolimus in oncology.
• To highlight the role of mTOR inhibition in cancer treatment.

Main Methods:

• Review of FDA and EMA approved indications for everolimus.
• Summary of ongoing phase 2 and phase 3 clinical trials.
• Focus on everolimus's mechanism as a protein kinase inhibitor.

Main Results:

• Everolimus is approved for advanced renal cell carcinoma, tuberous sclerosis-associated SEGA, pancreatic neuroendocrine tumors, and HR+/HER2- breast cancer.
• The drug demonstrates promising clinical activity in other cancer types.
• Multiple trials are investigating everolimus's efficacy alone and in combination therapies.

Conclusions:

• Everolimus is an established mTOR inhibitor with significant applications in oncology.
• Further clinical trials are essential to fully understand its therapeutic potential in various cancers.
• The mTOR pathway remains a key target for cancer therapy development.